Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity
AC Mares, S Chatterjee… - Current Opinion in …, 2022 - journals.lww.com
AC Mares, S Chatterjee, D Mukherjee
Current Opinion in Cardiology, 2022•journals.lww.com… Cardiovascular disease is the most common cause of morbidity and mortality worldwide,
and the risk is heightened in the presence of obesity. We review semaglutide, a drug
recently approved for chronic weight management in adults with obesity or who are
overweight. … Furthermore, the magnitude of weight loss achieved with semaglutide 2.4 mg
in this study was greater than that seen with liraglutide and other approved antiobesity
medications in similar patient populations [19▪] . …
and the risk is heightened in the presence of obesity. We review semaglutide, a drug
recently approved for chronic weight management in adults with obesity or who are
overweight. … Furthermore, the magnitude of weight loss achieved with semaglutide 2.4 mg
in this study was greater than that seen with liraglutide and other approved antiobesity
medications in similar patient populations [19▪] . …
Summary
Semaglutide offers adults with obesity or overweight a new treatment in conjunction with a weight management program consisting of reduced calorie diet and increased physical activity.
Lippincott Williams & Wilkins以上显示的是最相近的搜索结果。 查看全部搜索结果